This paper, published in the Canadian Journal of Kidney Health and Disease by CITF-funded researchers Drs. Matthew Oliver and Michelle Hladunewich (Sunnybrook Health Sciences Centre), presents the protocol for a new study aimed at characterizing the strength and duration of immune responses to COVID-19 vaccines in people living with chronic kidney disease (CKD).
A CITF-funded study, published in preprint and not yet peer-reviewed, demonstrates that third and fourth doses of vaccine sustain and broaden immune responses to SARS-CoV-2 in adults with immune-mediated inflammatory diseases (IMIDs). The authors conclude that this supports the recommendation for three- and four-dose primary series vaccine regimens in this population.
In a peer-reviewed paper published in Viruses, a CITF-funded study led by Dr Mohammad-Ali Jenabian (Université du Québec à Montréal, UQAM), along with Dr. Aslam Anis (University of British Columbia) found that a third dose of COVID-19 vaccines induced robust cellular immune responses in people living with HIV that are comparable to what is observed in individuals without HIV.
A CITF-funded study published in The Journal of Rheumatology highlighted that people with chronic immune-mediated inflammatory diseases (IMIDs) perceived the benefits of COVID-19 vaccination as outweighing their concerns over rare, though serious side effects and potential disease flare.
A CITF-funded study conducted by Dr. Matthew Oliver (University of Toronto) and his team revealed that estimates of vaccine effectiveness (VE) in individuals diagnosed with chronic kidney disease are consistent across three common study designs: test-negative, pseudo-test-negative, and cohort studies.
A CITF-funded study, published in AIDS and led by Drs. Cecilia Costiniuk (McGill University) and Aslam Anis (University of British Columbia, found that vaccine-induced antibodies to SARS-CoV-2 were elicited in over 90% of people living with HIV (PLWS). Of those, most (92%), maintained those antibodies for six months following a second dose, although this percentage is less than it was for HIV-negative controls.
CITF-funded research from Drs. Matthew Oliver and Michelle Hladunewich (University of Toronto), now published in Transplantation Direct, found that over 50% of kidney transplant recipients (KTRs) lacked Omicron-specific neutralizing antibodies one month following a third vaccine dose. Antibody levels in those that developed the Omicron-specific antibodies were well preserved at 3 months.
A CITF-funded study published in AIDS, from Mark Brockman and Zabrina Brumme (Simon Fraser University and BC Centre for Excellence in HIV/AIDS), along with Drs. Aslam Anis and Marc Romney (University of British Columbia) showed that the antibody responses induced by a third dose of COVID-19 vaccine were as durable in people living with HIV (PLWH) receiving antiretroviral therapy (ART) as in individuals without HIV.
A CITF-funded study published in the International Journal of Infectious Diseases showed that two doses of COVID-19 vaccine were effective at protecting against SARS-CoV-2 infections in people living with HIV (PLWH) during the pre-Omicron era.
A CITF-funded study, published in preprint, and not yet peer-reviewed, from Mark Brockman and Zabrina Brumme (Simon Fraser University and BC Centre for Excellence in HIV/AIDS), along with Drs. Aslam Anis and Marc Romney (University of British Columbia) showed that the antibody responses induced by a third dose of COVID-19 vaccine were as durable in people living with HIV (PLWH) receiving antiretroviral therapy (ART) as in individuals without HIV.